Boston Partners Buys Shares of 426,636 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Partners acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 426,636 shares of the company's stock, valued at approximately $15,778,000. Boston Partners owned about 0.89% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AMPH. Victory Capital Management Inc. boosted its position in Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company's stock valued at $10,605,000 after buying an additional 21,530 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $957,000. XTX Topco Ltd bought a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $674,000. Finally, Geode Capital Management LLC increased its position in Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after buying an additional 14,015 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday.

Amphastar Pharmaceuticals Stock Down 0.2 %

Shares of AMPH stock traded down $0.07 during mid-day trading on Tuesday, hitting $28.39. The company's stock had a trading volume of 713,226 shares, compared to its average volume of 427,152. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 9.46, a PEG ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96. The business has a 50-day moving average price of $31.72 and a 200 day moving average price of $40.36.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.